Derek Archila
Stock Analyst at Wells Fargo
(4.33)
# 407
Out of 5,130 analysts
216
Total ratings
54.79%
Success rate
15.87%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Overweight | $297 → $322 | $202.99 | +58.63% | 15 | Jan 9, 2026 | |
| GLUE Monte Rosa Therapeutics | Maintains: Overweight | $22 → $30 | $24.28 | +23.56% | 9 | Jan 8, 2026 | |
| VTYX Ventyx Biosciences | Downgrades: Equal-Weight | $14 | $13.81 | +1.38% | 6 | Jan 8, 2026 | |
| ALMS Alumis | Maintains: Overweight | $17 → $39 | $19.56 | +99.39% | 2 | Jan 6, 2026 | |
| ARGX argenx SE | Maintains: Overweight | $1,316 → $1,264 | $788.49 | +60.31% | 14 | Dec 16, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $21 → $30 | $19.30 | +55.44% | 7 | Dec 16, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $31 → $33 | $8.32 | +296.63% | 4 | Dec 16, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $91 → $109 | $78.14 | +39.49% | 1 | Dec 16, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $69 → $116 | $74.77 | +55.14% | 10 | Dec 9, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $19 → $25 | $9.15 | +173.22% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $116 | $106.87 | +8.54% | 11 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $27 | $5.25 | +414.29% | 4 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $18 → $28 | $25.30 | +10.67% | 5 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $84 | $77.25 | +8.74% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $395 → $479 | $398.29 | +20.26% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $12.07 | +24.28% | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $123 → $106 | $43.00 | +146.51% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $81 | $44.67 | +81.33% | 4 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $30 | $44.04 | -31.88% | 4 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $6.20 | -19.35% | 12 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $32 | $27.30 | +17.22% | 13 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $10 | $2.14 | +367.29% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $25 → $1 | $0.71 | +40.31% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $38 | $27.38 | +38.79% | 4 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $30 | $12.23 | +145.30% | 1 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $2.10 | -4.76% | 11 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $3.74 | +33.69% | 5 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $27 → $26 | $31.73 | -18.06% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $129 | $101.02 | +27.70% | 6 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $3.60 | +316.67% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $23.17 | -39.58% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $26.03 | +72.88% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $3.88 | +415.46% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.83 | +272.67% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $33.11 | +482.91% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $72.70 | -43.60% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $15.82 | +911.38% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $17.01 | +252.73% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $7.33 | +295.63% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.39 | +3,497.12% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $21.25 | +140.00% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $15.08 | +483.55% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $23.53 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $32.01 | - | 2 | Aug 3, 2017 |
Ascendis Pharma
Jan 9, 2026
Maintains: Overweight
Price Target: $297 → $322
Current: $202.99
Upside: +58.63%
Monte Rosa Therapeutics
Jan 8, 2026
Maintains: Overweight
Price Target: $22 → $30
Current: $24.28
Upside: +23.56%
Ventyx Biosciences
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $14
Current: $13.81
Upside: +1.38%
Alumis
Jan 6, 2026
Maintains: Overweight
Price Target: $17 → $39
Current: $19.56
Upside: +99.39%
argenx SE
Dec 16, 2025
Maintains: Overweight
Price Target: $1,316 → $1,264
Current: $788.49
Upside: +60.31%
Nurix Therapeutics
Dec 16, 2025
Maintains: Overweight
Price Target: $21 → $30
Current: $19.30
Upside: +55.44%
Kyverna Therapeutics
Dec 16, 2025
Maintains: Overweight
Price Target: $31 → $33
Current: $8.32
Upside: +296.63%
Disc Medicine
Dec 16, 2025
Maintains: Overweight
Price Target: $91 → $109
Current: $78.14
Upside: +39.49%
Kymera Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $69 → $116
Current: $74.77
Upside: +55.14%
ORIC Pharmaceuticals
Dec 8, 2025
Maintains: Overweight
Price Target: $19 → $25
Current: $9.15
Upside: +173.22%
Dec 8, 2025
Maintains: Overweight
Price Target: $97 → $116
Current: $106.87
Upside: +8.54%
Nov 19, 2025
Maintains: Overweight
Price Target: $14 → $27
Current: $5.25
Upside: +414.29%
Nov 14, 2025
Upgrades: Overweight
Price Target: $18 → $28
Current: $25.30
Upside: +10.67%
Nov 11, 2025
Maintains: Overweight
Price Target: $76 → $84
Current: $77.25
Upside: +8.74%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $395 → $479
Current: $398.29
Upside: +20.26%
Nov 6, 2025
Maintains: Overweight
Price Target: $16 → $15
Current: $12.07
Upside: +24.28%
Nov 5, 2025
Maintains: Overweight
Price Target: $123 → $106
Current: $43.00
Upside: +146.51%
Nov 5, 2025
Maintains: Overweight
Price Target: $51 → $81
Current: $44.67
Upside: +81.33%
Oct 21, 2025
Maintains: Equal-Weight
Price Target: $36 → $30
Current: $44.04
Upside: -31.88%
Oct 17, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $6.20
Upside: -19.35%
Oct 15, 2025
Upgrades: Overweight
Price Target: $29 → $32
Current: $27.30
Upside: +17.22%
Sep 23, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $2.14
Upside: +367.29%
Sep 16, 2025
Downgrades: Equal-Weight
Price Target: $25 → $1
Current: $0.71
Upside: +40.31%
Aug 20, 2025
Maintains: Overweight
Price Target: $44 → $38
Current: $27.38
Upside: +38.79%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $40 → $30
Current: $12.23
Upside: +145.30%
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $2.10
Upside: -4.76%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $3.74
Upside: +33.69%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $27 → $26
Current: $31.73
Upside: -18.06%
Jul 10, 2025
Maintains: Overweight
Price Target: $91 → $129
Current: $101.02
Upside: +27.70%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $3.60
Upside: +316.67%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $23.17
Upside: -39.58%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $26.03
Upside: +72.88%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $3.88
Upside: +415.46%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $4.83
Upside: +272.67%
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $33.11
Upside: +482.91%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $72.70
Upside: -43.60%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $15.82
Upside: +911.38%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $17.01
Upside: +252.73%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $7.33
Upside: +295.63%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.39
Upside: +3,497.12%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $21.25
Upside: +140.00%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $15.08
Upside: +483.55%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $23.53
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $32.01
Upside: -